

[Primaquine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

ATC codes: [P01BA03](#)

EMLc

Indication

Malaria due to *Plasmodium falciparum* ICD11 code: [1F40](#)

INN

Primaquine

Medicine type

Chemical agent

List type

Core

Additional notes

For use to reduce the transmission of *Plasmodium falciparum* and for radical cure of *Plasmodium vivax* and *Plasmodium ovale* infections.

Formulations

Oral > Solid > tablet: 7.5 mg (as phosphate) ; 15 mg (as phosphate)

EML status history

First added in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Primaquine](#)

DrugBank

[Primaquine](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to update the footnote with the listing for primaquine to specify use only for reducing the transmission of *Plasmodium falciparum* and to achieve radical cure of *Plasmodium vivax* and *Plasmodium ovale* infections.